Premium
Ramipril‐associated lichen planus pemphigoides
Author(s) -
OGG G.S.,
BHOGAL B.S.,
HASHIMOTO T.,
COLEMAN R.,
BARKER J.N.W.N.
Publication year - 1997
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1997.5761550.x
Subject(s) - ramipril , staining , bullous pemphigoid , medicine , pathology , basement membrane , antigen , dermatology , autoantibody , immunology , antibody , blood pressure
Summary We report the first case of lichen planus pemphigoide (LPP) secondary to ingestion of ramipril, an angiotensin‐converting enzyme inhibitor. Clinical, histological and immunofluorescent findings were all consistent with a diagnosis of LPP. Linear basement membrane zone (BMZ) staining with IgG and C3 was only seen at the rood of split‐skin preparations and circulating autoantibody to the BMZ was present at a titre of 1/100. Controlled immunoblotting of epidermal extracts detected the bullous pemphigoid antigens of 230 and 180 kDa.